Skip to main content

Advertisement

Log in

HIV-Associated Sensory Neuropathy: Risk Factors and Genetics

  • Neuropathic Pain (R Raja, Section editor)
  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

HIV-associated sensory neuropathy (HIV-SN) remains a common neurological complication of HIV infection despite the introduction of effective antiretroviral therapies. Exposure to neurotoxic antiretroviral drugs and increasing age have consistently been identified as risk factors for HIV-SN, while comorbid conditions with underlying predisposition to cause peripheral neuropathy (eg, diabetes mellitus, malnutrition, isoniazid exposure), ethnicity, and increasing height also have been implicated. Genetic association studies have identified genes affecting mitochondrial function and genes involved in the inflammatory response that modify the risk for HIV-SN among patients exposed to neurotoxic antiretrovirals. However, there is a lack of data on clinical, demographic, and genetic risk factors for HIV-SN in the modern era, with the rate of HIV-SN remaining unacceptably high despite the introduction of safer medications. Thus, more work is required to identify the principal factors that increase an individual’s risk for HIV-SN so that effective preventative or therapeutic strategies can be implemented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance

  1. Brew BJ. The peripheral nerve complications of human immunodeficiency virus (HIV) infection. Muscle Nerve. 2003;28:542–52.

    Article  PubMed  CAS  Google Scholar 

  2. Cherry C, McArthur J, Hoy J, et al. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol. 2003;26:195–207.

    Article  PubMed  CAS  Google Scholar 

  3. Cornblath D, Hoke A. Recent advances in HIV neuropathy. Curr Opin Neurol. 2006;19:446–50.

    Article  PubMed  Google Scholar 

  4. Keswani S, Pardo C, Cherry C, et al. HIV-associated sensory neuropathies. AIDS. 2002;16:2105–17.

    Article  PubMed  Google Scholar 

  5. Johnson D, Corthals S, Walker B, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011;29:797–804.

    Article  PubMed  CAS  Google Scholar 

  6. Nikitin A, Chudakova D, Strokov I, et al. Leu54Phe and Val762Ala polymorphisms in the poly(ADP-ribose)polymerase-1 gene are associated with diabetic polyneuropathy in Russian type 1 diabetic patients. Diabetes Res Clin Pract. 2008;79:446–52.

    Article  PubMed  CAS  Google Scholar 

  7. Tapp R, Shaw J, de Courten M, et al. Foot complications in Type 2 diabetes: an Australian population-based study. Diabet Med. 2003;20:105–13.

    Article  PubMed  CAS  Google Scholar 

  8. •• Cherry C, Affandi J, Imran D, et al. Age and height predict neuropathy risk in HIV patients prescribed stavudine. Neurology. 2009;73:315–20. This is a multicenter study showing that age and height are consistent risk factors for HIV-SN across diverse population groups.

    Article  PubMed  CAS  Google Scholar 

  9. • Maritz J, Benatar M, Dave J, et al. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve. 2010;41:599–606. This article describes risk factors for HIV-SN in black African HIV-positive patients exposed to antiretroviral therapy and patients who were treatment naïve.

    PubMed  Google Scholar 

  10. Shurie J, Deribew A. Assessment of the prevalence of distal symmetrical polyneuropathy and its risk factors among HAART-treated and untreated HIV infected individuals. Ethiop Med J. 2010;48:85–93.

    PubMed  Google Scholar 

  11. Smyth K, Affandi J, McArthur J, et al. Prevalence and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993–2006. HIV Med. 2007;8:367–73.

    Article  PubMed  CAS  Google Scholar 

  12. Wright E, Brew B, Arayawichanont A, et al. Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology. 2008;71:50–6.

    Article  PubMed  CAS  Google Scholar 

  13. • Wadley A, Cherry C, Price P, et al. HIV neuropathy risk factors and symptom characterization in Stavudine-Exposed South Africans. J Pain Symptom Manage. 2011;41:700–6. This article provides a description of the symptomatology and risk factors for HIV-SN in black Africans.

    Article  PubMed  Google Scholar 

  14. Tagliati M, Grinnell J, Godbold J, et al. Peripheral nerve function in HIV infection. Clinical, electrophysiologic, and laboratory findings. Arch Neurology. 1999;56:84–9.

    Article  CAS  Google Scholar 

  15. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med. 2008;9:660–74.

    Article  PubMed  Google Scholar 

  16. Kamerman P, Mitchell D. Current perspectives on HIV-related pain and its management: insights from sub-Saharan Africa. Pain Manage. 2011;1:587–96.

    Article  Google Scholar 

  17. Beadles W, Jahn A, Weigel R, et al. Peripheral neuropathy in HIV-positive patients at an antiretroviral clinic in Lilongwe, Malawi. Trop Doct. 2009;39:78–80.

    Article  PubMed  CAS  Google Scholar 

  18. •• Phillips T, Cherry C, Cox S, et al. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2010;5:e14433. This is an excellent review and meta-analysis of randomized controlled clinical trials investigating the pharmacological treatment of painful HIV-SN.

    Article  PubMed  CAS  Google Scholar 

  19. Bouhassira D, Attal N, Willer J-C, et al. Painful and painless peripheral sensory neuropathies due to HIV infection: a comparison using quantitative sensory evaluation. Pain. 1999;80:265–73.

    Article  PubMed  CAS  Google Scholar 

  20. Huengsberg M, Winer J, Ross J, et al. Thermosensory threshold: a sensitive test of HIV associated peripheral neuropathy? J Neurovirol. 1998;4:433–7.

    Article  PubMed  CAS  Google Scholar 

  21. •• Ellis R, Rosario D, Clifford D, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010;67:552–8. This is the first study to report on the continued high prevalence of HIV-SN in patients receiving modern cART.

    Article  PubMed  Google Scholar 

  22. Kandiah P, Atadzhanov M, Kvalsund M, et al. Evaluating the diagnostic capacity of a single-question neuropathy screen (SQNS) in HIV positive Zambian adults. J Neurol Neurosurg Psychiatry. 2010;81:1380–1.

    Article  PubMed  Google Scholar 

  23. Robinson-Papp J, Morgello S, Vaida F, et al. Association of self-reported painful symptoms with clinical and neurophysiologic signs in HIV-associated sensory neuropathy. Pain. 2010;151:732–6.

    Article  PubMed  CAS  Google Scholar 

  24. Cherry C, Wesselingh S, Lal L, et al. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology. 2005;65:1778–81.

    Article  PubMed  Google Scholar 

  25. Barohn R, Gronseth G, LeForce B, et al. Peripheral nervous system involvement in a large cohort of Human Immunodeficiency Virus-infected individuals. Arch Neurol. 1993;50:167–70.

    Article  PubMed  CAS  Google Scholar 

  26. So Y, Holtzman D, Abrams D, et al. Peripheral neuropathy associated with Acquired Immunodeficiency Syndrome—Prevalence and clinical features from a population-based survey. Arch Neurol. 1988;45:945–8.

    Article  PubMed  CAS  Google Scholar 

  27. Childs E, Lyles R, Selnes O, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology. 1999;52:607–13.

    PubMed  CAS  Google Scholar 

  28. Woolley I, Faragher M, Ugoni A, et al. An analysis of factors associated with HIV-related peripheral neuropathy. Neurol Infect Epidemiol. 1997;1997:33–7.

    Google Scholar 

  29. Forna F, Liechty C, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2007;44:456–62.

    Article  PubMed  CAS  Google Scholar 

  30. • Kamerman P, Moss P, Weber J, et al.: Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in vitro experimental models. J Peripher Nerv Syst 2012, In press. This is a concise review of the pathogenesis of HIV-SN based on in vivo and in vitro models of the neuropathy.

  31. •• Choi Y, Townend J, Vincent T, et al. Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa. J Neurovirol. 2011;17:166–75. This article provides invaluable data on the neurological complications of HIV-2 infection.

    Article  Google Scholar 

  32. Dalakas M, Yarchoan R, Spitzer R, et al. Treatment of human immunodeficiency virus-related polyneuropathy with 3′-azido-2′,3′–dideoxythymidine. Ann Neurology. 1988;23:S92–4.

    Article  Google Scholar 

  33. Markus R, Brew B. HIV-1 peripheral neuropathy and combination antiretroviral therapy. Lancet. 1998;352:1906–7.

    Article  PubMed  CAS  Google Scholar 

  34. Bacellar H, Munoz A, Miller E, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985–1992. Neurology. 1994;44:1892–900.

    PubMed  CAS  Google Scholar 

  35. Ances B, Vaida F, Rosario D, et al. Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS. 2009;23:2317–22.

    Article  PubMed  CAS  Google Scholar 

  36. Kumarasamy N, Venkatesh K, Cecelia A, et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS. 2008;22:227–44.

    Google Scholar 

  37. Hawkins C, Achenbach C, Fryda W, et al. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr. 2007;45:305–10.

    Google Scholar 

  38. Nakamoto BK, McMurtray A, Davis J, et al. Incident neuropathy in HIV-infected patients on HAART. AIDS Res Hum Retroviruses. 2010;26:759–65.

    Article  PubMed  CAS  Google Scholar 

  39. • Anziska Y, Helzner EP, Crystal H, et al. The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US women. J Neurol Sci 2011, doi: 10.1016/j.jns.2011.11.009. This was the first study to report an association between HIV-SN and being of African descent.

  40. Browne M, Mayer K, Chafee S, et al. 2′,3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis. 1993;167:21–9.

    Article  PubMed  CAS  Google Scholar 

  41. Lambert J, Seidlin M, Reichmann R, et al. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial N Engl J Med. 1990;322:1333–40.

    CAS  Google Scholar 

  42. Yarchoan R, Perno C, Thomas R, et al. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988;1:76–81.

    Article  PubMed  CAS  Google Scholar 

  43. World Health Organization: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Available at http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf. Accessed 28 November 2011.

  44. Esteban P, Thahn T, Bravo J, et al. Malnutrition associated with increased risk of peripheral neuropathy in Peruvian children with HIV infection. J Acquir Immune Defic Syndr. 2009;52:656–568.

    PubMed  Google Scholar 

  45. Ferrari L, Levine J. Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms. Eur J Neurosci. 2010;32:811–8.

    Article  PubMed  Google Scholar 

  46. Cheng Y, Gregg E, Kahn H, et al. Peripheral insensate neuropathy-a tall problem for US adults? Am J Epidemiol. 2006;164:873–80.

    Article  PubMed  Google Scholar 

  47. Shikuma C, Ananworanich J, Valcour V, et al. Correlates of epidermal nerve fiber density in HIV-infected individuals without neuropathy prior to initiation of potent ART [abstract 173]. Presented at 17th Conf Retrovir Oppor Infect. San Francisco, USA; February 16–19, 2010.

  48. Menezes C, Maskew M, Sanne I, et al. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis. 2011;11:244.

    Article  PubMed  CAS  Google Scholar 

  49. Sacktor N, Nakasujja N, Skolasky R, et al. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology. 2009;72:165–70.

    Article  PubMed  CAS  Google Scholar 

  50. •• Mehta S, Ahmed A, Laverty M, et al. Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy. Clin Infect Dis. 2011;53:490–6. This is an excellent prospective, longitudinal study on the incidence of HIV-SN in patients starting stavudine-based treatment.

    Article  PubMed  CAS  Google Scholar 

  51. Lichtenstein K, Armon C, Baron A, et al. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. CLin Infect Dis. 2005;40:148–57.

    Article  PubMed  Google Scholar 

  52. Pettersen J, Jones G, Worthington C, et al. Sensory Neuropathy in Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol. 2006;59:816–24.

    Article  PubMed  CAS  Google Scholar 

  53. Evans S, Ellis R, Chen H, et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS. 2011;25:919–28.

    Article  PubMed  Google Scholar 

  54. Ellis R, Marquie-Beck J, Delaney P, et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008;64:566–72.

    Article  PubMed  CAS  Google Scholar 

  55. Cherry C, Affandi J, Brew B, et al. Ethnicity is an independent predictor of neuropathy risk in HIV patients [abstract 416]. Presented at 18th Conf Retrovir Oppor Infect. Boston, USA; 27 February - 2 March, 2011.

  56. Cherry C, Affandi J, Brew B, et al. Hepatitis C seropositivity is not a risk factor for sensory neuropathy among HIV patients. Neurology. 2010;74:1538–42.

    Article  PubMed  CAS  Google Scholar 

  57. Clifford D, Smurzynski M, Park L, et al. Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology. 2009;73:309–14.

    Article  PubMed  CAS  Google Scholar 

  58. Sithinamsuwan P, Punthanamongkol S, Valcour V, et al. Frequency and characteristics of HIV-associated sensory neuropathy among HIV patients in Bangkok, Thailand. J Acquir Immune Defic Syndr. 2008;49:456–8.

    Article  PubMed  Google Scholar 

  59. Jamisse L, Balkus J, Hitti J, et al. Antiretroviral-associated toxicity among HIV1-seropositive pregnant women in mazambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr. 2007;44:371–6.

    Article  PubMed  CAS  Google Scholar 

  60. Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy. The Manhattan HIV Brain Bank. Arch Neurol. 2004;61:546–51.

    Article  PubMed  Google Scholar 

  61. Schifitto G, McDermott M, McArthur J, et al. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology. 2005;64:842–8.

    Article  PubMed  CAS  Google Scholar 

  62. Attal N, Lanteri-Minet M, Laurent B, et al. The specific disease burden of neuropathic pain: Results of a French nationwide survey. Pain. 2011;152:2836–43.

    Article  PubMed  Google Scholar 

  63. Simpson DM, Haidich AB, Schifitto G, et al. Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS. 2002;16:407–12.

    Article  PubMed  CAS  Google Scholar 

  64. Polydefkis M, Yiannoutsos CT, Cohen BA, et al. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology. 2002;58:115–9.

    PubMed  CAS  Google Scholar 

  65. Zhou L, Kitch DW, Evans SR, et al. Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy. Neurology. 2007;68:2113–9.

    Article  PubMed  CAS  Google Scholar 

  66. Lucey B, Clifford D, Creighton J, et al. Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy. AIDS Care. 2011;23:921–8.

    Article  PubMed  Google Scholar 

  67. Evans S, Weinberg BA, Spielman L, et al. Assessing negative thoughts in response to pain among people with HIV. Pain. 2003;105:239–45.

    Article  PubMed  Google Scholar 

  68. Department of Health and Human Services USA: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed 28 November 2011.

  69. Hahn K, Triolo A, Hauer P, et al. Impaired reinnervation in HIV infection following experimental denervation. Neurology. 2007;68:1251–6.

    Article  PubMed  CAS  Google Scholar 

  70. Mills E, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155:209–16.

    PubMed  Google Scholar 

  71. van Sighem A, Gras L, Reiss P, et al. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24:1527–35.

    Article  PubMed  Google Scholar 

  72. Winkler C. Is there a genetic basis for health disparities in human immunodeficiency virus disease? Mt Sinai J Med. 2010;77:149–59.

    Article  PubMed  Google Scholar 

  73. Macgregor S, Cornes BK, Martin NG, et al. Bias, precision and heritability of self-reported and clinically measured height in Australian twins. Hum Genet. 2006;120:571–80.

    Article  PubMed  Google Scholar 

  74. Perola M, Sammalisto S, Hiekkalinna T, et al. Combined genome scans for body stature in 6,602 European twins: evidence for common Caucasian loci. PLoS Genet. 2007;3:e97.

    Article  PubMed  Google Scholar 

  75. Silventoinen K, Sammalisto S, Perola M, et al. Heritability of adult body height: a comparative study of twin cohorts in eight countries. Twin Res. 2003;6:399–408.

    PubMed  Google Scholar 

  76. Costarelli S, Torti C, Gatta LB, et al. No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. J Acquir Immune Defic Syndr. 2007;46:255–6.

    Article  PubMed  Google Scholar 

  77. Canter JA, Haas DW, Kallianpur AR, et al. The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J. 2008;8:71–7.

    Article  PubMed  CAS  Google Scholar 

  78. • Canter JA, Robbins GK, Selph D, et al. African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J Infect Dis. 2010;201:1703–7. This is the first study to investigate population-specific mitochondrial risk factors for HIV-SN in individuals of African descent.

    Article  PubMed  CAS  Google Scholar 

  79. Hulgan T, Haas DW, Haines JL, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS. 2005;19:1341–9.

    Article  PubMed  Google Scholar 

  80. Chen X, Goudsmit J, van der Kuyl AC. Lack of correlation between length variation in the DNA polymerase gamma gene CAG repeat and lactic acidosis or neuropathy during antiretroviral treatment. AIDS Res Hum Retroviruses. 2002;18:531–4.

    Article  PubMed  CAS  Google Scholar 

  81. Kallianpur AR, Hulgan T, Canter JA, et al. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS. 2006;20:1503–13.

    Article  PubMed  CAS  Google Scholar 

  82. Affandi JS, Price P, Imran D, et al. Can we predict neuropathy risk before stavudine prescription in a resource-limited setting? AIDS Res Hum Retroviruses. 2008;24:1281–4.

    Article  PubMed  CAS  Google Scholar 

  83. Cherry CL, Rosenow A, Affandi JS, et al. Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual’s NRTI-SN risk. AIDS Res Hum Retroviruses. 2008;24:117–23.

    Article  PubMed  CAS  Google Scholar 

  84. • Chew CSN, Cherry CL, Imran D, et al. Tumour necrosis factor haplotypes associated with sensory neuropathy in Asian and Caucasian human immunodeficiency virus patients. Tissue Antigens. 2011;77:126–30. This article demonstrates the importance of genes in the central MHC as risk factors for HIV-SN across ethnic groups.

    Article  PubMed  CAS  Google Scholar 

  85. Koczor CA, Lewis W. Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opin Drug Metab Toxicol. 2010;6:1493–504.

    Article  PubMed  CAS  Google Scholar 

  86. Chan SS, Copeland WC. DNA polymerase gamma and mitochondrial disease: understanding the consequence of POLG mutations. Biochim Biophys Acta. 2009;1787:312–9.

    Article  PubMed  CAS  Google Scholar 

  87. Parkkila S, Niemela O, Britton RS, et al. Molecular aspects of iron absorption and HFE expression. Gastroenterology. 2001;121:1489–96.

    Article  PubMed  CAS  Google Scholar 

  88. Horowitz MP, Greenamyre JT. Mitochondrial iron metabolism and its role in neurodegeneration. J Alzheimers Dis. 2010;20 Suppl 2:S551–68.

    PubMed  Google Scholar 

  89. Drakesmith H, Prentice A. Viral infection and iron metabolism. Nat Rev Microbiol. 2008;6:541–52.

    Article  PubMed  CAS  Google Scholar 

  90. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol. 2001;154:193–206.

    Article  PubMed  CAS  Google Scholar 

  91. United Nations Programme on HIV/AIDS: Global report: UNAIDS report on the global AIDS epidemic 2010. Available at http://www.unaids.org/documents/20101123_GlobalReport_em.pdf. Accessed 4 December 2011.

  92. •• Kallianpur AR, Hulgan T. Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics. 2009;10:623–37. This is an excellent review of the genetic risk factors associated with risk of NRTI-induced HIV-SN.

    Article  PubMed  CAS  Google Scholar 

  93. Young EE, Lariviere WR, Belfer I. Genetic basis of pain variability: recent advances. J Med Genet. 2011. doi:10.1136/jmedgenet-2011-100386.

  94. Tegeder I, Costigan M, Griffin RS, et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med. 2006;12:1269–77.

    Article  PubMed  CAS  Google Scholar 

  95. Wadley AL, Lombard Z, Cherry CL, Price P, Kamerman PR. Analysis of a previously identified 'pain protective' haplotype and individual polymorphisms in the GCH1 gene in Africans with HIV-associated sensory neuropathy: a genetic association study. J Acquir Immune Defic Syndr 2012, In press.

  96. Dorsey SG, Leitch CC, Renn CL, et al. Genome-wide screen identifies drug-induced regulation of the gene giant axonal neuropathy (Gan) in a mouse model of antiretroviral-induced painful peripheral neuropathy. Biol Res Nurs. 2009;11:7–16.

    Article  PubMed  CAS  Google Scholar 

  97. Maratou K, Wallace VCJ, Hasnie FS, et al. Comparison of dorsal root ganglion gene expression in rat models of traumatic and HIV-associated neuropathic pain. Eur J Pain. 2009;13:387–98.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

Dr. Peter R. Kamerman has grants pending from Pfizer (global); has received honoraria from Pfizer (Africa and Middle East); has received payment for the development of educational presentations from Pfizer (South Africa); and has undertaken market research for Partners in Research. A. L. Wadley: none. Dr. Catherine Cherry has served on advisory boards for Roche Australia, Gilead Sciences Australia, and Bristol-Myers Squibb Australia.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter R. Kamerman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kamerman, P.R., Wadley, A.L. & Cherry, C.L. HIV-Associated Sensory Neuropathy: Risk Factors and Genetics. Curr Pain Headache Rep 16, 226–236 (2012). https://doi.org/10.1007/s11916-012-0257-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-012-0257-z

Keywords

Navigation